Chronic hepatitis B
Conditions
Interventions
nucleos(t)ide analogue monotherapy,taken once dail:nucleos(t)ide analogue monotherapy,taken once dail
Group B:alpha-interferon monotherapy,taken once week for 1year
Group C:nucleos(t)ide analogue combined with alpha-interferon,for 2 years
Sponsors
Beijing Youan Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 18 to 70 years old. 2.Consecutive adult patients with chronic hepatitis B were enrolled in the study. 3.Additional eligibility criteria were as follows: laboratory test results that were positive for both HBsAg and HBeAg for at least 6 months before the initiation of the study, HBV DNA>105copies/ml, alanine aminotransferase (ALT) levels>60 IU/L
Exclusion criteria
Exclusion criteria: Exclusion criteria included evidence of decompensated liver disease, co-infection with HAV, HCV, HDV and/or HIV, comorbidities or severe psychiatric disease, a neutrophil absolute count<1.0×109/L, a platelet count<5×109/L, a history of alcohol or drug abuse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBVDNA;HBeAg;HBsA; | — |
Countries
China
Contacts
Public ContactXinyue Chen
Outcome results
None listed